<- Go Home
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Market Cap
$155.2B
Volume
6.1M
Cash and Equivalents
$725.0M
EBITDA
$4.5B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$12.0B
Profit Margin
68.45%
52 Week High
$107.17
52 Week Low
$71.82
Dividend
N/A
Price / Book Value
6.99
Price / Earnings
76.56
Price / Tangible Book Value
-91.62
Enterprise Value
$166.5B
Enterprise Value / EBITDA
35.92
Operating Income
$3.2B
Return on Equity
9.50%
Return on Assets
5.28
Cash and Short Term Investments
$725.0M
Debt
$11.7B
Equity
$22.4B
Revenue
$17.6B
Unlevered FCF
$2.5B
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium